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Abstract The aim of this study was to present a new concept of 
site-directed reduction of disulfide bonds based upon the use of 
an affinity ligand harbouring a readily oxidizable dithiol. The 
cysteine bond involved in the acetylcholine binding site of the 
AChoR was specifically reduced by a carbamylcholine analogue. 
The ligand, in its oxidized form, was characterized by an affinity 
constant of 20/~M for the agonist binding site. In its dithiol form, 
it specifically reduced the disulfide between Cys-192 and Cys-193 
on the a-subunits of the nicotinic acetylcholine receptor. This 
reduction needed 10 times lower concentration when carried out 
with site-directed reducing agent (ARA) than with DTT, and was 
highly specific for the a-subunits. The contribution of the carbam- 
ylcholine moiety of the site-directed reducing agent was clearly 
demonstrated in kinetic studies where reduction abilities of ARA, 
DTT and the methylated analogue of ARA (MeRA) were com- 
pared. At the same concentration (20/~M), DTT and MeRA had 
a 25 times lower initial rate of reduction than ARA. With 200 ~M 
of DTT this initial reduction was still 4 times lower. Furthermore, 
the use of a maleimido undecagold cluster which specifically la- 
beled the reduced nicotinic receptor opens the way to structural 
analysis of the agonist binding site by electron microscopy. These 
results demonstrate the potency of this kind of site-directed re- 
ducing agent for structural study of receptors or enzymes involv- 
ing a disulfide bond in their active site. 
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1. Introduction 
Disulfide bonds are known to be essential elements of protein 
structure. They can be easily reduced (e.g. with DTT, fl-mer- 
captoethanol, NaBH4) and the cysteines can be specifically 
labeled (e.g. with iodoacetic acid, NEM). When a disulfide 
bond is located near a protein active site, its cysteines can be 
specifically labeled by an affinity probe after DTT reduction. 
However, in such an approach, some other disulfide bonds may 
also be reduced. We propose here a new concept in which a 
disulfide bond involved in an active site is specifically reduced 
and labeled with reactants having no affinity for this site. We 
constructed a site-directed disulfide reducing agent able in the 
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one hand to specifically recognize the active site of the protein 
and on the other to reduce the adjacent disulfide bond. A 
well-documented model for testing this concept is the disulfide 
bond located between Cys-192 and Cys-193 of the a-subunit of 
the nicotinic acetylcholine r ceptor (AChoR) [1,2]. These resi- 
dues are involved in the binding site of acetylcholine and have 
already been labeled, after reduction with DTT, with an agonist 
(BAC) [3-7] or an antagonist (MBTA) [8-10]. 
This paper describes the use of an analogue of carbam- 
ylcholine (ARA) harbouring a readily oxidizable dithiol, with 
an affinity constant of 20 ¢tM (in its oxidized state) for the 
agonist binding site of the AChoR, able to specifically reduce 
the Cys-192 Cys-193 bond on the ~-subunits. The kinetic study 
of this reduction showed a much faster initial rate for ARA 
than for DTT at the same concentration. The affinity contribu- 
tion in this difference was confirmed by studying the reduction 
ability of an ARA analogue where the ethyl-trimethylammo- 
nium moiety was replaced by a methyl group. 
This site-directed reduction offers the possibility of labeling 
the nicotinic receptor with a maleimido undecagold cluster and 
opens up new vistas as to the localization of the acetylcholine 
binding site in the AChoR, by electron microscopy. 
2. Materials and methods 
The synthesis ofthe site-directed disulfide reducing agent (ARA) was 
described elsewhere [11]. 
2.1. AChoR preparation 
AChoR membrane fragments were prepared from Torpedo marmo- 
rata electric organs as previously described [12]. Receptor membranes 
were purified by alkali treatment according to Neubig et al. [13] for their 
use in labeling experiments with [3H]NEM. In this case, the membrane 
suspension consisted of 1-3 nmol of toxin binding sites per mg of 
proteins. Free sulfhydryls were alkylated by excess NEM (5 mM) for 
45 min at room temperature followed by dialysis against 50 mM phos- 
phate buffer, pH 7.4, 50 mM NaC1 (P buffer). After alkylation, the 
receptor was desensitized byincubation with Proadifen (15 mM, 1 h). 
2.2. Apparent affinity constants determination of oxydized ARA for 
A ChoR 
The association kinetics of [3H]a-toxin to AChoR with increasing 
concentrations of oxydized affinity reagent were determined byfollow- 
ing the method previously described [14,15], in presence or not of a 
non-competitive blocker, and allowed us to determine the apparent 
inhibition constants (Ki ~-tox) of the reducing agent on the acetylcholine 
binding site for the receptor in the resting and desensitized states. 
The affinity constant (Kj vcv) for the non-competitive blocker site was 
determined by competition between [3H]phencyclidine (Dositek, 
France; 50 Ci/mmol, 1 nM) and the oxidized form of the reducing agent 
(concentration range between 1 ¢tM and 5 mM) after 30 min incubation 
with carbamylcholine (0.1 mM). 
2.3. Labeling of AChoR with [SH]NEM after reduction with the 
affinity reducing agent or with DTT 
Receptor preparations were diluted in degassed P buffer to about 
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0.4 mg/ml (determined by the method of Lowry [16]). The reducing 
agent was added at different concentrations and was allowed to react 
for 20 min with ARA and for 30 rain with DTT. Membranes were 
pelleted in Eppendorf tubes for 15 rain at 17,600 x g and resuspended 
in the same buffer. [3H]NEM (1 Ci/mmol, 1 mM) was then added to 
a final concentration f 20 pM for 1 h at room temperature. Following 
another centrifugation, the pellets were resuspended in P buffer in order 
to obtain protein concentrations of about 1.4 mg/ml and incubated for 
3 h at room temperature in denaturating buffer. 38 pg of proteins were 
subjected to SDS-PAGE which was performed according to Laemmli 
[17] on a 10% polyacrylamide g l. After staining (Coomassie brillant 
R-250) and destaining, the gel was cut into 1 mm slices which were 
digested with Lipoluma-Lumasolve solution (Luma-LSC, The Nether- 
lands) and counted for tritium radioactivity. 
2.4. Protection experiments 
Assays were made by incubating carbamylcholine (200 pM) prior to 
the reduction step. Other protection experiments were carried out with 
NEM (20 pM) or maleimido undecagold cluster (20/.tM) incubated 
after the reduction step, prior to the alkylation with [3H]NEM. 
2.5. Quantification ftoxin binding sites in native, reduced, and reduced- 
alkylated receptor 
The concentration f toxin binding sites was measured after incuba- 
tion of 15 pmol of [~H]a-toxin (tritiated in our laboratory at a specific 
radioactivity of 27 Ci/mmol) with AChoR (0-10 pmol) in 500 ~1 of 
Ringer buffer. After 1 h, 2 x 200 pl was filtered through HAWP filters 
(Millipore), and after drying under light and addition of scintillating 
solution (Lipoluma-LSC, The Netherlands) the radioactivity was 
counted. 
Acetylcholinesterase activity, measured by the method of Ellman 
[18], was inhibited by the addition of Tacrine (5 pM). 
For protection experiments, NEM (20 pM) or gold cluster (20 pM) 
D. Servent et al./FEBS Letters 360 (1995) 261-265 
were added to the affinity-reduced membranes prior to tl~e determina- 
tion of toxin sites. 
2.6. Kinetic experiment 
Reduction with ARA, DTT or MeRA was carried out as described 
above; aliquots of the reduced receptor were removed at different times 
and blocked with an excess of BAC (10 raM) prior to the quantification 
of a-toxin binding sites. The kinetics of loss of toxin binding sites was 
inversely proportional to the disulfide bond reduction. 
3. Results 
3.1. Synthesis of  ARA and MeRA 
ARA (Scheme 1) was synthesized as described earlier [11]. 
MeRA (Scheme 1) was obtained in 62% yield by coupling 
4-amino-l,2-dithiane [11] with methylchloroformate in dry 
tetrahydrofurane. 
3.2. Apparent affinity constant determination of the oxidized 
form of ARA and MeRA for AChoR 
The affinity for the acetylcholine binding site was determined 
from measurements of the inhibition of the initial rate of toxin 
binding on the nicotinic receptor, using increasing concentra- 
tions of ligand. In the receptor desensitized state (in the pres- 
ence of the non-competitive blocker proadifen) a constant 
Ki~.tox of 20 pM was measured for the oxidized form 
of ARA (Scheme 1). This was 10 times higher than the constant 
measured with the receptor in its resting state (data not shown). 
For the methyl analogue (MeRA), the affinity constant for the 
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Scheme l. Chemical structures of ARA, oxidized ARA, MeRA and maleimido undecagold cluster. 
D. Servent et al./FEBS Letters 360 (1995) 261-265 263 
E 
75000 
60000 r- 
45000 
30000 
15000 
al )ha 
t- -  
~- delta gamma 
~ " , , .  beta i 
i /'/'\ .1' "\ "-. "~/" ~ i i j- 
' i 
F 
q 
J 
L 
4 
0 5 10 15 20 25 30 35 40 45 50 55 60 
Gel s l ices (mm) 
Fig. 1. Alkylation of AChoR membranes by [3H]NEM after reduction with the affinity reducing agent or DTT. Alkali-treated membranes were 
reduced by ARA (--, 20/tM) or DTT (---, 20 pM: -. -, 200 ¢tM) for 30 min at room temperature. After centrifugation and resuspension in phosphate 
buffer the membranes were incubated with [3H]NEM (1 Ci/mmol) at 20 ~M. Electrophoresis was run on 10% polyacrylamide g ls and the gel cut 
into 1 mm slices, digested and the radioactivity counted. 
desensitized receptor was greater than 1 mM. The affinity for 
the non-competitive blockers ite was determined by competi- 
tion with [3H]phencyclidine in the presence of the agonist car- 
bamylcholine, which induced the desensitized state (highest af- 
finity for the ligands). An affinity constant Ki PCP of about 1 mM 
was obtained for ARA and showed its specificity for the cholin- 
ergic site. 
3.3. Labeling of the reduced A ChoR by [3H]NEM 
When alkaline-treated membranes were reacted with 
[3H]NEM (1 mM) after disulfide reduction with the affinity 
reducing agent at a concentration f20 ¢tM, the electrophoresis 
profile of labeled proteins howed an exclusive incorporation 
of radioactivity on the ~-subunit (Fig. 1). No significant label- 
ing of the fl-, 7- or 8-subunits occurred. 
When the receptor was incubated with an excess of ARA (up 
to 0.2 mM), the labeling on the ~-subunit did not increase in 
comparison with the assay performed with 20/zM reagent, 
however, non-specific reduction on other proteins appeared. 
Furthermore, concentrations lower than 10/tM caused a de- 
crease in [3H]NEM alkylation on the c~-subunit, explained by 
a lower occupancy of the agonist binding site (data not shown). 
If the reduction was made in the presence of 20/tM DTT 
instead of ARA, the incorporation of radioactivity on the ~- 
subunit represented only 15% of the labeling after reduction 
with the affinity reagent. Furthermore, a concentration f DTT 
10 times higher (0.2 raM) was necessary to observe a compara- 
ble labeling on the c~-subunit by [3H]NEM, but in this case the 
radioactive background was substantially more important and 
non-~-subunits and non-receptor p oteins were labeled (Fig. 1). 
The relatively important labeling on the d-subunit could be 
explained by the partial reduction of the dimeric form of the 
AChoR which is present in the membrane preparation and 
which involves a disulfide bond between two 8-subunits. 
Incubation of the reduced receptor with thiol reagents, i.e 
non-radioactive NEM or maleimido undecagold cluster 
(Scheme 1) prior to [3H]NEM labeling totally abolished the 
incorporation ofradioactivity (Fig. 2). A protection experiment 
was carried out with carbamylcholine (preincubated at 200/.tM) 
in which an 80% decrease in the cz-subunit labeling was ob- 
served (Fig. 2), demonstrating the specificity of the reduction 
step. 
3.4. Kinetic of  the disulfide bond reduction by ARA, DTT or 
MeRA 
In order to confirm the affinity step for ARA reduction, a
kinetic study of the disulfide bond reduction by the different 
reducing agents was carried out. At different imes, the free 
sulfhydryls were reacted with an excess of bromoacetylcholine 
(BAC, 10 mM) and the residual c~-toxin binding sites were 
quantified. These experiments showed that the time-course 
that is required to completely reduce the disulfide bond adja- 
cent to the ligand binding site was about 5 min in the case of 
ARA (20/.tM), 20 min for DTT (200/zM), in agreement with 
previous reports [4], and up to 2 h for MeRA or DTT at 20/tM 
(Fig. 3). The comparison of the initial rate of reduction between 
ARA, MeRA and DTT (Fig. 3) showed clearly the involvement 
of an affinity step of ARA which reacted about 25 times faster 
on the disulfide bond than DTT or MeRA at the same concen- 
tration (20/tM). At 200/tM, the initial rate of reduction with 
DTT was still nearly 4 times lower than with ARA at 20/.tM. 
No loss of toxin binding sites was observed after DTT reduc- 
tion or alkylation with NEM or maleimido undecagold cluster. 
However, a loss of about 35% of the binding sites was observed 
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in the case of ARA-reduced receptor in comparison with non- 
reduced or DTT-reduced ones. This loss could be explained by 
the formation of mixed disulfides between the cysteines from 
the receptor and the reducing agent. When ARA reduction was 
followed by DTT reduction the toxin binding sites were recov- 
ered (data not shown). 
4. Discussion 
In this paper, we describe a new approach for the site-di- 
rected reduction of disulfide bonds of the AChoR using a 
site-directed isulfide reducing agent. We built a carbam- 
ylcholine analogue (ARA) harbouring a dithiol which forms, 
like DTT, a favorable 1,2-dithiane upon oxydation. The lower 
affinity for the AChoR of the reducing agent (20 ¢tM, in its 
oxidized form) as compared to carbamylcholine (Ki = 0.5 ¢tM 
[15]) could be due to the addition on the polar carbamide nd 
of carbamylcholine of a hydrophobic non-polar educing moi- 
ety. 
The exclusive labeling of the cz-subunit by [3H]NEM follow- 
ing the site-directed reduction with ARA (Fig. 1) can be com- 
pared with previous reports in which a non-specific reducing 
agent (DTT) was used and the cysteinyl residues in the active 
site were labeled with an affinity probe (MBTA or BAC [1-10]). 
However, the site-directed reduction with ARA required both 
a reduced time and a lower concentration of reducing agent 
(Figs. 1 and 3). It allowed the selective labeling of cystinyl 
residues of the functional sites by thiol reagents having no 
affinity for that site. Furthermore, considering the size of our 
reagent, our data confirmed the previous proposals that the 
disulfide Cys-19~Cys-193 bond is located at about 1 nm from 
the quaternary ammonium binding site [1,2,10]. Indeed, reduc- 
tion experiments carried out with an ARA analogue possessing 
a methylene group between the carbonyl and the nitrogen of 
the carbamylcholine moiety showed no affinity process for this 
reducing agent, and the reduction proceeded in the same way 
as with MeRA or DTT (20/.tM) (data not shown). 
The involvement of a specific recognition step in the reduc- 
tion process with ARA was shown by the protective ffect of 
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Fig. 2. Specificity of the site-directed reduction. Alkali-treated mem- 
branes were treated as in Fig. 1. The membranes were incubated for 30 
min either with carbamylcholine (200 ¢tM) prior to the reduction with 
ARA or with NEM (20 pM) or maleimido gold cluster (20 #M) prior 
to the alkylation with [3H]NEM. The amount of radioactivity incorpo- 
rated into the ct-subunits was compared to the control experiment (as 
in Fig. 1). The labeling after eduction with DTT (20#M) was obtained 
with the same protocol. 
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Fig. 3. Time-course reduction of the disulfide bond by ARA, MeRA 
or DTT. Aliquots of the receptor incubated with the different reducing 
agents were removed at different imes, blocked with excess BAC (10 
mM) and used to determine the residual toxin binding sites as described 
in section 2. 
carbamylcholine on this reduction (Fig. 2) and by the charac- 
teristic kinetic properties of ARA in comparison with DTT or 
MeRA (Fig. 3). The fast initial rate of reduction with ARA 
could be explained by the high local concentration of reducing 
agent in proximity to the disulfide bond of the receptor, due to 
the affinity property of ARA, which is not the case for its 
methyl analogue (MeRA) or for DTT. Hence, the site-directed 
reduction leads to a more specific labeling of the ~-subunit (no 
radioactivity incorporated in non-~-subunits) using a 10 times 
lower concentration of reducing agent. 
It should be noted that preliminary experiments made with 
higher DTT concentrations (2 or 20 raM) induced a significant 
increase in radioactivity incorporation i  the c~-subunit com- 
pared with DTT (0.2 mM) or with the affinity reducing agent 
(20 ¢tM) (data not shown). Possibly, the other extracellular 
disulfide bond between Cys-128 and Cys-142 on the c~-subunit 
was thus reduced only at high concentrations of DTT. No such 
reduction occurs in the presence of ARA. At this high DTT 
concentrations, labeling appeared on non<z-subunits and in 
particular on the ~-subunit which has an additional extracellu- 
lar disulfide bond with a neighbouring receptor. The reduction 
of disulfide bonds depends on the concentration of reducing 
agent. In the case of the AChoR, the vicinal cysteine-cysteine 
bond was shown to be much more fragile than other cysteines, 
and hence it is possible to reduce this bond almost exclusively 
using appropriately low concentrations of DTT (Fig. 1). Such 
selectivity may not always be observed in the case of other 
receptors or enzymes possessing several accessible disulfide 
bonds. 
However, after the ARA reduction, about 35% of the toxin 
binding sites were lost compared to the non-reduced or DTT- 
reduced receptor. This loss was probably due to mixed disul- 
fides between the receptor and the reactant, confirmed by the 
recovery of all these sites by an additional DTT reduction. The 
synthesis of new carbamylcholine analogues i now in progress 
to avoid the formation of disulfide bridges between the receptor 
and the reducing ligand. 
In a previous report [19], we described the stereospecific 
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monomodifrcation f a snake toxin with maleimido undecagold 
cluster for the determination f the three-dimensional localiza- 
tion of its binding site on the AChoR. We have now specifically 
reduced a disulfide bond in the vicinity of the agonist binding 
site and labeled it with the same cluster. This labeling inhibited 
the incorporation of [3H]NEM in the cysteinyl residues (Fig. 2). 
These preliminary results open the way for the labeling of the 
acetylcholine binding site by an electron-dense cluster, making 
it available for study by electron microscopy. This could be 
particularly helpful to confirm previous reports [20] that postu- 
lated that the acetylcholine binding site was about 30 • from 
the bilayer surface on the a-subunit, and it should help to 
localize the site in the central pit or on the external surface of 
the AChoR. 
The AChoR reduction by the site-directed reducing agent 
will also be an interesting tool for the use of aromatic arsenox- 
ides as selective labeling reagents for the nicotinic receptor. In 
fact, the biological effect of arsenicals was previously investi- 
gated [21] and particularly for labeling the AChoR by forming 
covalent yet reversible complexes with pairs of thiols [22,23]. 
The use of an affinity reducing agent which specifically reduces 
the disulfide bond at the vicinity of the agonist binding site 
could greatly increase the efficacy of the arsenical labeling and 
so the detection of many subtypes of neuronal and muscular 
AChoR. 
This new concept of selective disulfide bond reduction could 
probably be extended to other receptors or enzymes where a 
disulfide bond is suspected to be involved in or near the ligand 
binding site or catalytic site. For instance, the glycine receptor 
is, along with the nicotinic receptor, a member of the ligand- 
gated ion channel group which possesses two extracellular di- 
sulfide bonds on the a-subunit. It could be possible to investi- 
gate with appropriately derivatized strychnine the proximity of 
a disulfide bridge to the antagonist binding site. 
Furthermore, for biochemical studies on AChoR using cell 
lines, site-directed disulfide reducing agents could help to avoid 
the cytotoxic effects of the more usual reductants such as DTT. 
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